[CAS NO. 129497-78-5] Verteporfin

Name: Verteporfin
Brand: Arctom Scientific
SKU: HY-B0146

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [129497-78-5]

Store

Catalog

HY-B0146

Brand

MCE

CAS

129497-78-5

DESCRIPTION [129497-78-5]

Overview

MDL	MFCD28098202
Molecular Weight	718.79
Molecular Formula	C82H84N8O16
SMILES	C[C@]1(/C2=C/C(N3)=C4C)C(C(/C=C(C(C)=C/5C=C)\NC5=C/C6=N/C(C(CCC(OC)=O)=C6C)=C\C3=C4CCC(O)=O)=N2)=CC=C(C(OC)=O)[C@H]1C(OC)=O.C[C@]7(/C8=C/C(N9)=C%10C)C(C(/C=C(C(C)=C/%11C=C)\NC%11=C/C%12=N/C(C(CCC(O)=O)=C%12C)=C\C9=C%10CCC(OC)=O)=N8)=CC=C(C(OC)=O)[C@H]7C(OC)=O

For research use only. We do not sell to patients.

101 Publications Citing Use of MCE

Summary

Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis ^[1] . Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation ^[3] .

IC50 & Target

IC50: YAP-TEAD interaction

In Vitro

Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI ₅₀ ) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI ₅₀ for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 µM, 2.11 µM, and 5.61 µM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells ^[1] . Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and NSC 125973 shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Verteporfin (10 mg/kg, c.s.c.) and BMS-354825 significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00135837	Novartis\|QLT Inc.	Age-Related Macular Degeneration	June 2003	Phase 4
NCT03033225	Mayo Clinic\|National Cancer Institute (NCI)	Advanced Pancreatic Carcinoma\|Locally Advanced Pancreatic Carcinoma\|Metastatic Pancreatic Carcinoma\|Pancreatic Neoplasm\|Stage II Pancreatic Cancer AJCC v8\|Stage IIA Pancreatic Cancer AJCC v8\|Stage IIB Pancreatic Cancer AJCC v8\|Stage III Pancreatic Cancer AJCC v8\|Stage IV Pancreatic Cancer AJCC v8\|Unresectable Pancreatic Carcinoma	December 6, 2016	Phase 2
NCT00007969	QLT Inc.\|National Cancer Institute (NCI)	Melanoma (Skin)	October 2000	Phase 1\|Phase 2
NCT00546936	Barnes Retina Institute\|Genentech, Inc.	Presumed Ocular Histoplasmosis (POHS)	October 2007	Phase 2
NCT02702700	Centre Hospitalier Universitaire Vaudois	Pleural Effusion, Malignant	January 2016	Phase 1
NCT02457026	Duke University\|Bausch & Lomb Incorporated	Neovascular Age-related Macular Degeneration	January 2016	Not Applicable
NCT00002647	Medical College of Wisconsin\|National Cancer Institute (NCI)	Brain and Central Nervous System Tumors\|Metastatic Cancer	May 1994	Phase 1
NCT00049959	QLT Inc.\|Novartis	Basal Cell Carcinoma\|Nevoid Basal Cell Carcinoma Syndrome\|Gorlin Syndrome		Phase 3
NCT00433017	Novartis	Macular Degeneration\|Choroidal Neovascularization	May 2007	Phase 2\|Phase 3
NCT00574093	Fondazione G.B. Bietti, IRCCS	Neovascular Age Related Macular Degeneration	January 2008	Phase 2
NCT01846273	Novartis Pharmaceuticals\|Novartis	Age-related Macular Degeneration\|Polypoidal Choroidal Vasculopathy	August 7, 2013	Phase 4
NCT00570193	Mid-Atlantic Retina Consultations, Inc.	Choroidal Neovascularization\|Macular Degeneration	December 2006	Phase 1\|Phase 2
NCT01325181	Jang Won Heo\|Novartis Korea Ltd.\|Seoul National University Hospital	Chronic Central Serous Chorioretinopathy	July 2009	Phase 1\|Phase 2
NCT01922102	Novartis Pharmaceuticals\|Novartis	Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)	September 11, 2013	Phase 3
NCT03067051	SpectraCure AB	Recurrent Prostate Cancer	March 21, 2017	Phase 1\|Phase 2
NCT00347399	Asociación para Evitar la Ceguera en México	Age Related Macular Degeneration	March 2006	Phase 2
NCT00729846	California Retina Consultants\|Novartis	Age Related Macular Degeneration\|Choroidal Neovascularization\|Macular Edema	May 2006	Phase 2
NCT04075136	Wake Forest University Health Sciences\|Modulight	Exudative Age Related Macular Degeneration	November 2022	Phase 4
NCT00390208	Bay Area Retina Associates\|QLT Inc.	Age Related Macular Degeneration	August 2006	Phase 2
NCT00426998	Retinal Consultants Medical Group	Choroidal Neovascularization\|Macular Degeneration	April 2006	Phase 2
NCT01019668	Shin Kong Wu Ho-Su Memorial Hospital	Central Serous Chorioretinopathy	November 2008	Not Applicable
NCT01746875	Norwegian University of Science and Technology	Macular Degeneration\|Retinal Detachment	February 2014	Not Applicable
NCT00436553	Novartis	Macular Degeneration\|Choroidal Neovascularization	February 2007	Phase 3
NCT00331435	Ophthalmic PDT Study Group	Age Related Macular Degeneration	June 2006	Phase 4
NCT00211445	Manhattan Eye, Ear & Throat Hospital	Chronic Central Serous Chorioretinopathy	July 2002	Phase 2
NCT02872064	University College, London	Breast Neoplasms	January 2013	Not Applicable
NCT00403442	Vitreous -Retina- Macula Consultants of New York\|QLT Inc.	Macular Degeneration	September 2006	Phase 1
NCT01256580	Massachusetts Eye and Ear Infirmary	Choroidal Neovascularization\|Myopia\|Punctate Inner Choroidopathy (PIC)\|Multifocal Choroiditis\|Ocular Histoplasmosis Syndrome\|Central Serous Chorioretinopathy (CSC)\|Angioid Streaks\|Trauma, or Hereditary Eye Diseases	August 2010	Not Applicable
NCT00527475	Texas Retina Associates\|Novartis	Macular Degeneration	May 2007	Phase 2
NCT00359164	University of British Columbia	Macular Degeneration	July 2006	Phase 2
NCT00211419	Manhattan Eye, Ear & Throat Hospital\|Alcon Research	Maculopathy, Age-Related		Phase 1
NCT01217944	Novartis Pharmaceuticals\|Novartis	Pathological Myopia	October 2010	Phase 3
NCT03459144	Sun Yat-sen University	Polypoidal Choroidal Vasculopathy	December 1, 2012	Not Applicable
NCT00473642	Oklahoma State University Center for Health Sciences\|Novartis	Age-Related Maculopathy\|Choroidal Neovascularization	May 2007	Phase 4
NCT05589974	Helse Stavanger HF	Central Serous Chorioretinopathy	October 1, 2022
NCT00390026	St. Erik Eye Hospital	Age-Related Macular Degeneration	November 2006	Phase 3
NCT04590664	Emory University\|National Cancer Institute (NCI)	Glioblastoma\|Recurrent Glioblastoma	January 15, 2021	Phase 1\|Phase 2
NCT00674323	Novartis	Polypoidal Choroidal Vasculopathy	April 2008	Phase 4
NCT01570608	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Age Related Macular Degeneration	March 2007	Phase 3
NCT00242580	Novartis Pharmaceuticals\|QLT Inc.\|Novartis	Macular Degeneration\|Choroidal Neovascularization	September 2005	Phase 3
NCT02939274	Rogers Sciences Inc.	Metastatic Breast Cancer	October 2016	Phase 2
NCT00471406	Chonnam National University Hospital	Corneal Neovascularization		Not Applicable
NCT00134667	Eyetech Pharmaceuticals\|Pfizer	Age-Related Macular Degeneration	March 2005	Phase 4
NCT00492284	QLT Inc.	Choroidal Neovascularization\|Macular Degeneration	July 2007	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : ≥ 200 mg/mL ( 278.25 mM )

DMF : 10 mg/mL ( 13.91 mM ; ultrasonic and warming and heat to 60°C)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.3912 mL	6.9561 mL	13.9123 mL
5 mM	0.2782 mL	1.3912 mL	2.7825 mL
10 mM	0.1391 mL	0.6956 mL	1.3912 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 5 mg/mL (6.96 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 5 mg/mL (6.96 mM); Clear solution
3.

Add each solvent one by one: 10% DMF >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (3.48 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

24H,26H-Benzo[b]porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, (4R,4aS)-rel-

23H,25H-Benzo[b]porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans-

BPD-MA

CL 318952

Verteporfin

Visudyne